{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:03:01Z","timestamp":1789660981682,"version":"4.0.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jpsychires.2025.10.063","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T07:46:08Z","timestamp":1761723968000},"page":"237-244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy and tolerability of brexpiprazole augmentation of SSRI therapy in PTSD: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"192","author":[{"given":"Martin","family":"Kotochinsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus Rodrigues","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Hayasaki","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmood","family":"Balogun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima Norbu","family":"Sherpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Gonzalez","family":"Lezana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2025.10.063_bib1","series-title":"Clinical Practice Guideline for the Treatment of Posttraumatic Stress Disorder (PTSD) in Adults","year":"2017"},{"issue":"1","key":"10.1016\/j.jpsychires.2025.10.063_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/s12888-025-06783-7","article-title":"The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis","volume":"25","author":"Bai","year":"2025","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jpsychires.2025.10.063_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/NDT.S501207","article-title":"Preclinical evidence for the use of brexpiprazole + antidepressant treatment for major depressive disorder and post-traumatic stress disorder: a systematic review","volume":"21","author":"Brubaker","year":"2025","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"4","key":"10.1016\/j.jpsychires.2025.10.063_bib4","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2174\/1570159X21666230428091433","article-title":"Treatment of posttraumatic stress disorder: a state-of-the-art review","volume":"22","author":"Burback","year":"2024","journal-title":"Curr. Neuropharmacol."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.10.063_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1001\/jamapsychiatry.2024.3996","article-title":"Brexpiprazole and sertraline combination treatment in posttraumatic stress disorder: a phase 3 randomized clinical trial","volume":"82","author":"Davis","year":"2025","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"10.1016\/j.jpsychires.2025.10.063_bib6","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1080\/03007995.2023.2269839","article-title":"Patient journey before and after a formal post-traumatic stress disorder diagnosis in adults in the United States - a retrospective claims study","volume":"39","author":"Davis","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1356563","article-title":"Post-traumatic stress disorder: the role of the amygdala and potential therapeutic interventions \u2013 a review","volume":"15","author":"Davis","year":"2024","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib8","series-title":"VA\/DoD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder","year":"2023"},{"issue":"11","key":"10.1016\/j.jpsychires.2025.10.063_bib9","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00213-023-06333-7","article-title":"The effect of SSRIs on fear learning: a systematic review and meta-analysis","volume":"240","author":"Heesbeen","year":"2023","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.jpsychires.2025.10.063_bib10","doi-asserted-by":"crossref","first-page":"24m15577","DOI":"10.4088\/JCP.24m15577","article-title":"Brexpiprazole in combination with sertraline and as monotherapy in posttraumatic stress disorder: a full-factorial randomized clinical trial","volume":"86","author":"Hobart","year":"2025","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2025.10.063_bib11","article-title":"Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches","volume":"12","author":"Hoskins","year":"2021","journal-title":"Eur. J. Psychotraumatol."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.10.063_bib12","doi-asserted-by":"crossref","DOI":"10.1080\/20008066.2025.2452680","article-title":"Effectiveness in routine care: trauma-focused treatment for PTSD","volume":"16","author":"Kr\u00fcger-Gottschalk","year":"2025","journal-title":"Eur. J. Psychotraumatol."},{"issue":"9","key":"10.1016\/j.jpsychires.2025.10.063_bib13","article-title":"Post-traumatic stress disorder: a narrative review of pharmacological and psychotherapeutic interventions","volume":"15","author":"Mansour","year":"2023","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.jpsychires.2025.10.063_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1037\/pas0001098","article-title":"Reliable and clinically significant change in the clinician-administered PTSD scale for DSM-5 and PTSD checklist for DSM-5 among male veterans","volume":"34","author":"Marx","year":"2022","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib15","series-title":"StatPearls [Internet]. Treasure Island (FL)","article-title":"Veteran and military mental health issues. 2023 Aug 17","author":"Moore","year":"2025"},{"key":"10.1016\/j.jpsychires.2025.10.063_bib16","unstructured":"NCT01987960. Brexpiprazole as Adjunctive Therapy in PTSD: Study of Safety and Efficacy. Otsuka Pharmaceutical Development & Commercialization, Inc. Accessed June 27, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01987960."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib17","unstructured":"NCT04174170. A study of brexpiprazole in adult participants with posttraumatic stress disorder. Otsuka Pharmaceutical Development & Commercialization, Inc. Accessed June 27, 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04174170."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.10.063_bib18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1124\/jpet.114.218578","article-title":"Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization","volume":"351","author":"Oosterhof","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib19","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jclinepi.2021.03.001","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"134","author":"Page","year":"2021","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib20","unstructured":"PAXIL (paroxetine hydrochloride) [package insert]. Silver Spring, MD: U.S. Food and Drug Administration. Revised August 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020031s077lbl.pdf."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.brainres.2009.03.037","article-title":"Pharmacotherapy of PTSD: premises, principles, and priorities","volume":"1293","author":"Ravindran","year":"2009","journal-title":"Brain Res."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.10.063_bib22","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/jonm.13478","article-title":"Posttraumatic stress disorder in nurses in the United States: prevalence and effect on role","volume":"30","author":"Rodney","year":"2022","journal-title":"J. Nurs. Manag."},{"issue":"5","key":"10.1016\/j.jpsychires.2025.10.063_bib23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1176\/appi.ajp.20250110","article-title":"An update on psychotherapy for the treatment of PTSD","volume":"182","author":"Rothbaum","year":"2025","journal-title":"Am. J. Psychiatr."},{"issue":"9","key":"10.1016\/j.jpsychires.2025.10.063_bib24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/070674371405900902","article-title":"Posttraumatic stress disorder in adults: impact, comorbidity, risk factors, and treatment","volume":"59","author":"Sareen","year":"2014","journal-title":"Can. J. Psychiatr."},{"issue":"1","key":"10.1016\/j.jpsychires.2025.10.063_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41398-023-02708-8","article-title":"Fear extinction rescuing effects of dopamine and L-DOPA in the ventromedial prefrontal cortex","volume":"14","author":"Sartori","year":"2024","journal-title":"Transl. Psychiatry"},{"issue":"12","key":"10.1016\/j.jpsychires.2025.10.063_bib26","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1080\/03007995.2021.1978417","article-title":"Prevalence of post-traumatic stress disorder in the United States: a systematic literature review","volume":"37","author":"Schein","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib27","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41398-023-02660-7","article-title":"Impaired learning, memory, and extinction in posttraumatic stress disorder: translational meta-analysis of clinical and preclinical studies","volume":"13","author":"Sep","year":"2023","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.jpsychires.2025.10.063_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11126-017-9522-y","article-title":"Minimal clinically important differences (MCID) in assessing outcomes of post-traumatic stress disorder","volume":"89","author":"Stefanovics","year":"2018","journal-title":"Psychiatr. Q."},{"issue":"3","key":"10.1016\/j.jpsychires.2025.10.063_bib29","article-title":"Pharmacotherapy for post traumatic stress disorder (PTSD)","volume":"3","author":"Williams","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jpsychires.2025.10.063_bib30","unstructured":"ZOLOFT (sertraline hydrochloride) [package insert]. Silver Spring, MD: U.S. Food and Drug Administration. Revised August 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/019839s74s86s87_20990s35s44s45lbl.pdf."}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625006818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395625006818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:11:38Z","timestamp":1789657898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395625006818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S0022395625006818"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.10.063","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of brexpiprazole augmentation of SSRI therapy in PTSD: A systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2025.10.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}